Cervical Cancer

Viswanathan, Akila N.; Dizon, Don S.; Gien, Lilian T.; Koh, Wui-Jin

doi:10.1016/b978-0-323-24098-7.00058-7

Cited by 7 publications

(3 citation statements)

References 299 publications

(221 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is probable that this new classification is more precise to predict the pattern of treatment failure and survival outcomes for stage III cervical cancer patients than FIGO 2009. Although nowadays, the modern techniques of EBRT such as intensity-modulated radiation therapy (IMRT) are developed for many types of cancer, IMRT is not the standard technique for locally advanced cervical cancer [ 17 ]. Moreover, the proper position of applicator and packing for ICBT has limitation from narrowing of vagina due to the disease, and dose prescription at point A may be compromised.…”

Section: Discussionmentioning

confidence: 99%

Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion

Katanyoo

2017

J Gynecol Oncol

View full text Add to dashboard Cite

ObjectiveTo evaluate treatment outcomes between stage IIIB cervical cancer with and without lower third of vaginal invasion (LTI) in terms of response to treatment and overall survival (OS).MethodsMatching one patient with LTI for 2 patients without LTI who had completed treatment between 1995 and 2012 were conducted by using treatment modalities (radiation therapy [RT] alone vs. concurrent chemoradiation therapy [CCRT]) and tumor histology (squamous cell carcinoma [SCC] vs. adenocarcinoma [ADC]). Treatment outcomes including complete response (CR) rate of RT/CCRT, patterns of treatment failure and survival outcomes were analyzed.ResultsOf 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI. Most of the patients (83.8%) had tumor histology as SCC. The CR rates between stage IIIB without LTI and with LTI were 93.8% and 81.9% (p=0.009), and corresponding with disease progression at pelvis accounted for 18.2% and 34.4% (p=0.017), respectively. Distant metastasis was comparable between 2 groups of patients, 28.9% in patients without LTI and 29.5% in patients with LTI (p=0.988). The 2-year and 5-year OS of stage IIIB without LTI were 66.5% and 46.8% compared to stage IIIB with LTI which were 43.1% and 28.9% (p=0.004), respectively. For multivariable analysis, stage IIIB with LTI was only the influential factor on OS with hazard ratio (HR) of 1.63 (p=0.012).ConclusionStage IIIB cervical cancer patients with LTI have poorer treatment outcomes including response to treatment and survival outcomes than patients in the same stage without LTI.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion

Katanyoo

2017

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…As a result of the fact that those with cervical cancer typically present with a mass that is clinically limited to the pelvis, achieving locoregional disease control is the fundamental obstacle that must be overcome throughout therapy [19]. Patients with an illness limited to a specific area see unprecedented rates of cure after receiving individualized treatment depending on the features of their tumors (Table 4).…”

Section: Treatmentmentioning

confidence: 99%

Cervical Cancer

Natelauri

2023

Radiation Therapy

View full text Add to dashboard Cite

Cervical cancer is a worldwide public health problem. The leading cause of cervical cancer is persistent infection with high-risk human papillomavirus (HPV). Vaccines exist that protect against high-risk HPV types, and screening programs can detect signs of disease at an early stage, allowing for effective treatment and management of the condition. While being one of the most preventable and treatable forms of cancer, the mortality rate is high, especially in low- and middle-income countries. Early diagnoses, proper staging, and a multidisciplinary approach is the cornerstone of disease management. Surgical treatment, radiation therapy, chemotherapy, immune therapy, and supportive and palliative care are all essential parts of the complex treatment. A simple hysterectomy or brachytherapy for early-stage cervical cancer results in a 5-year OS of more than 98%. For selected patients, radical trachelectomy represents a fertility-sparing treatment option. Radiotherapy (RT), with or without cisplatin-based concurrent chemotherapy after radical or modified radical hysterectomy, is recommended for patients with intermediate- or high-risk features. RT, including brachytherapy plus concurrent chemotherapy, is the treatment of choice for patients with locally advanced disease. Irradiation often provides excellent short-term relief of pain and bleeding, particularly in patients with no history of prior RT.

show abstract

“…It is found to be the second most common type of tumor. It is found to have high mortality rate [1] which accounts for more than 500,000 new cases and approximately 275,000 deaths occur [2]. There are various methods used to treat cervical cancer with chemotherapy, radiotherapy, and surgery.…”

Section: Introductionmentioning

confidence: 99%

Treating Cervical Cancer With Herbs: A Review

Joseph

Dhanraj

Ramalingam

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Medicinal plants have been on the forefront where research on the anticancer agent is planned. This review mainly focuses on several such as medicinal plants Rosmarinus officinalis, Solanum nigrum, Kaffir lime, and Garcinia nujiangensis used in the treatment of cervical cancer and the secondary metabolites derived from different plant sources. Plant molecules such as cisplatin, curcumin (-)- epigallocatechin (EGC)-3-gallate, EGC, epicatechin- 3-gallate, and other catechins that have a wide range of biological properties and the molecular mechanism with different cells were reviewed. This review will promote the research on the development of a plant-derived anticancer drug with lesser or no side effects and aid in understanding the mechanism of action of several plant-derived molecules.

show abstract

Cervical Cancer

Cited by 7 publications

References 299 publications

Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion

Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion

Cervical Cancer

Treating Cervical Cancer With Herbs: A Review

Contact Info

Product

Resources

About